Literature DB >> 10942469

Should intravenous tocolysis be considered beyond 34 weeks' gestation?

S C Jones1, B C Brost, W T Brehm.   

Abstract

OBJECTIVE: Our purpose was to assess the incidence of respiratory distress syndrome in nonindigent women with uncomplicated preterm labor between 34 and 36 weeks' gestation. STUDY
DESIGN: All women seen between June 1, 1992, and April 15, 1999, with uncomplicated preterm labor and intact membranes and delivering between 34 and 36 weeks' gestation were analyzed. Rates of respiratory distress syndrome after delivery were calculated. A chi(2) analysis was performed, and a P value of <.05 was considered statistically significant.
RESULTS: Respiratory distress syndrome was noted in 8 (17.4%) of 46 infants delivered at 34 weeks' gestation, in comparison with 5 (6.3%) of 80 infants and 7 (4.2%) of 165 infants delivered at 35 and 36 weeks' gestation, respectively (P =.008). The rate of respiratory distress syndrome after delivery at 34 weeks was significantly higher than at 35 weeks (P =.048).
CONCLUSION: The rate of respiratory distress syndrome after delivery at 34 weeks is significantly higher than at either 35 or 36 weeks' gestation in our population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942469     DOI: 10.1067/mob.2000.107663

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

Review 1.  Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome.

Authors:  Diana M Bond; Philippa Middleton; Kate M Levett; David P van der Ham; Caroline A Crowther; Sarah L Buchanan; Jonathan Morris
Journal:  Cochrane Database Syst Rev       Date:  2017-03-03

2.  Impact of Changes in Maternal Age and Parity Distribution on the Increasing Trends in the Low Birth Weight and Very Low Birth Weight Rates in South Korea, 2005-2015.

Authors:  Yujin Oh; Jisuk Bae
Journal:  J Prev Med Public Health       Date:  2019-03-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.